Characterization of absorbable collagen sponges as rhBMP-2 carriers

International Journal of Pharmaceutics

Volumn 187, Issue 1, 1999, Pages 91-99

  Friess, W ^a   Uludag, H ^b   Foskett, S ^c   Biron, R ^c   Sargeant, C ^c  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF ALBERTA   (Canada)

^c PFIZER INC   (United States)

Author keywords

Bone morphogenetic protein; Collagen; Crosslinking; Sterilization

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; COLLAGEN; DRUG CARRIER;

ANIMAL EXPERIMENT; ARTICLE; BINDING SITE; CHEMICAL MODIFICATION; CROSS LINKING; DRUG RELEASE; DRUG STERILITY; IMPLANTATION; KINETICS; NONHUMAN; PH; PHARMACOKINETICS; PRIORITY JOURNAL; RAT; SPONGE; SUBCUTANEOUS DRUG ADMINISTRATION;

ABSORBABLE IMPLANTS; ANIMALS; ANIONS; BIOCOMPATIBLE MATERIALS; BONE MORPHOGENETIC PROTEINS; CHO CELLS; COLLAGEN; CRICETINAE; CROSS-LINKING REAGENTS; DRUG CARRIERS; HUMANS; HYDROGEN-ION CONCENTRATION; IODINE RADIOISOTOPES; PROTEIN ISOFORMS; RATS; RATS, LONG-EVANS; RECOMBINANT PROTEINS; STERILIZATION; TRANSFORMING GROWTH FACTOR BETA;

EID: 0032879991     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(99)00174-X     Document Type: Article

References (14)

1. Abbatiello S.E., Porter T.J. Anion-mediated precipitation of recombinant human bone morphogenetic protein (rhBMP-2) is dependent upon heparin binding N-terminal region. Protein Sci. 6:1997;99.
2. Friess W. Collagen-biomaterial for drug delivery. Eur. J. Pharm. Biopharm. 45:1998;113-136.
3. Friess W., Sargeant C. In vitro evaluation of rhBMP-2 in combination with a porous calcium phosphate device for bone regeneration. Proceed. Intern. Symp. Control. Rel. Bioact. Mater. 24:1997;895-896.
4. Friess W., Uludag H., Foskett S., Biron R. Bone regeneration with rhBMP-2 using absorbable collagen sponges-Influence of processing of ACS characteristics and formulation. Pharm. Develop. Technol. 4:1999;387-396.
5. Hubbell J.A. Biomaterials in tissue engineering. Biotechnology. 13:1995;565-576.
6. Israel D.I., Nove J., Kerns K.M., Moutsatsos I.K., Kaufman R.J. Expression and characterization of bone morphogenetic protein-2 in chinese hamster ovary cells. Grow. Fac. 13:1996;139-150.
7. Rathore S., Hammerstone K.M., Dansereau S., Porter T.J. N-terminal isoforms of recombinant human bone morphogenetic protein (rhBMP-2) are active in vitro and in vivo. Protein Sci. 4:1995;140.
8. Reich R.R., Burgess D.J. Ethylene oxide sterilization. Swarbrick J., Boylan J.C. Encyclopedia of Pharmaceutical Technology. 5:1992;315-336 Marcel Dekker, New York, USA.
9. Royce P.M., Kato T., Ohsaki K., Miura A. The enhancement of cellular infiltration and vascularisation of a collagenous dermal implant in the rat by platelet-derived growth factor BB. J. Dermatol. Sci. 10:1995;42-52.
10. Sampath K., Reddi H. Homology of bone-inductive proteins from human, monkey, bovine, and rat extracellular matrix. Proc. Natl. Acad. Sci. USA. 80:1983;6591-6595.
11. Slavin J., Nash J.R., Kingsnorth A.N. Effect of transforming growth factor beta and basic fibroblast growth factor on steroid impaired healing intestinal wound. Br. J. Surg. 79:1992;69-72.
12. Toolan B.C., Frenkel S.R., Pachence J.M., Yalowitz L., Alexander H. Effects of growth-factor-enhanced culture on a chondrocyte-collagen implant for cartilage repair. J. Biomed. Mater. Res. 31:1996;273-280.
13. Uludag, H., Friess, W., Williams, D., D'Augusta, D., Blake, C., Palmer, R., Biron, R., Wozney, J., 1998. An investigation of in vitro collagen sponge characteristics and in vivo rhBMP-2/sponge pharmacokinetics. Trans. Soc. Biomat. Meeting, San Diego, pp. 418.
14. Winn S.R., Uludag H., Hollinger J.O. Sustained release emphasizing recombinant human bone morphogenetic protein-2. Adv. Drug Del. Rev. 31:1998;303-318.